{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:29Z","timestamp":1761630389452},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,10,10]],"date-time":"2005-10-10T00:00:00Z","timestamp":1128902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,10,10]],"date-time":"2005-10-10T00:00:00Z","timestamp":1128902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1038\/sj.bmt.1705185","type":"journal-article","created":{"date-parts":[[2005,10,24]],"date-time":"2005-10-24T15:07:22Z","timestamp":1130166442000},"page":"1097-1101","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report"],"prefix":"10.1038","volume":"36","author":[{"given":"M Y","family":"Shapira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I B","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ackerstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Tsirigotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Gesundheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Zilberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Miron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Leubovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Or","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,10]]},"reference":[{"key":"BF1705185_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.139.6.719","volume":"139","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Christophers E, Langley R et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719\u2013727.","journal-title":"Arch Dermatol"},{"key":"BF1705185_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248\u2013255.","journal-title":"N Engl J Med"},{"key":"BF1705185_CR3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","volume":"76","author":"PJ Martin","year":"1990","unstructured":"Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft versus host disease: initial treatment. Blood 1990; 76: 1464\u20131472.","journal-title":"Blood"},{"key":"BF1705185_CR4","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","volume":"75","author":"D Weisdorf","year":"1990","unstructured":"Weisdorf D, Haake R, Blazar B et al. Treatment of moderate\/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024\u20131030.","journal-title":"Blood"},{"key":"BF1705185_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.bmt.1701899","volume":"24","author":"R Martino","year":"1999","unstructured":"Martino R, Romero P, Subira M et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 1999; 24: 283\u2013287.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705185_CR6","first-page":"273","volume":"17","author":"T Pugatsch","year":"1996","unstructured":"Pugatsch T, Oppenheim A, Slavin S . Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273\u2013275.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705185_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1126\/science.3029872","volume":"235","author":"Y Nakamura","year":"1987","unstructured":"Nakamura Y, Leppert O, O\u2019Connel P et al. Variable number of tandem repeats (VNTR) markets for human gene mapping. Science 1987; 235: 1616\u20131622.","journal-title":"Science"},{"key":"BF1705185_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1126\/science.285.5426.412","volume":"285","author":"WD Shlomchik","year":"1999","unstructured":"Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412\u2013415.","journal-title":"Science"},{"key":"BF1705185_CR9","first-page":"297","volume":"109","author":"L Chatenoud","year":"2005","unstructured":"Chatenoud L . Monoclonal antibody-based strategies in autoimmunity and transplantation. Methods Mol Med 2005; 109: 297\u2013328.","journal-title":"Methods Mol Med"},{"key":"BF1705185_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00277-004-0890-7","volume":"83","author":"R Zeiser","year":"2004","unstructured":"Zeiser R, Marks R, Bertz H, Finke J . Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551\u2013565.","journal-title":"Ann Hematol"},{"key":"BF1705185_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00007890-198411000-00005","volume":"38","author":"JW Gratama","year":"1984","unstructured":"Gratama JW, Jansen J, Lipovich RA et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 1984; 38: 469\u2013474.","journal-title":"Transplantation"},{"key":"BF1705185_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0301-472X(03)00228-5","volume":"31","author":"HR Chena","year":"2003","unstructured":"Chena HR, Jia SQ, Wanga HX et al. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 2003; 31: 1019\u20131025.","journal-title":"Exp Hematol"},{"key":"BF1705185_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","volume":"102","author":"EC Morris","year":"2003","unstructured":"Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404\u2013406.","journal-title":"Blood"},{"key":"BF1705185_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1517\/13543784.11.9.1271","volume":"11","author":"DA Jacobsohn","year":"2002","unstructured":"Jacobsohn DA . Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 2002; 11: 1271\u20131280.","journal-title":"Expert Opin Investig Drugs"},{"key":"BF1705185_CR15","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2002-03-0985","volume":"100","author":"JH Antin","year":"2002","unstructured":"Antin JH, Weisdorf D, Neuberg D et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479\u20133482.","journal-title":"Blood"},{"key":"BF1705185_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/sj.bmt.1702638","volume":"26","author":"M Andolina","year":"2000","unstructured":"Andolina M, Rabusin M, Maximova N, Di Leo G . Etanercept in graft-versus-host disease. Bone Marrow Transplant 2000; 26: 929.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705185_CR17","first-page":"631","volume":"2","author":"SJ Bashir","year":"2001","unstructured":"Bashir SJ, Maibach HI . Alefacept (Biogen). Curr Opin Investig Drugs 2001; 2: 631\u2013634.","journal-title":"Curr Opin Investig Drugs"},{"key":"BF1705185_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00007890-199602150-00004","volume":"61","author":"RJ Kaplon","year":"1996","unstructured":"Kaplon RJ, Hochman PS, Michler RE et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996; 61: 356\u2013363.","journal-title":"Transplantation"},{"key":"BF1705185_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1067\/mjd.2002.127247","volume":"47","author":"GG Krueger","year":"2002","unstructured":"Krueger GG, Papp KA, Stough DB et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821\u2013833.","journal-title":"J Am Acad Dermatol"},{"key":"BF1705185_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.139.6.719","volume":"139","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Christophers E, Langley R et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719\u2013727.","journal-title":"Arch Dermatol"},{"key":"BF1705185_CR21","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood.V92.11.4066","volume":"92","author":"D Przepiorka","year":"1998","unstructured":"Przepiorka D, Phillips GL, Ratanatharathorn V et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92: 4066\u20134071.","journal-title":"Blood"},{"key":"BF1705185_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/eji.200323586","volume":"33","author":"JC Cooper","year":"2003","unstructured":"Cooper JC, Morgan G, Harding S et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003; 33: 666\u2013675.","journal-title":"Eur J Immunol"},{"key":"BF1705185_CR23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1073\/pnas.0409569102","volume":"102","author":"F Chamian","year":"2005","unstructured":"Chamian F, Lowes MA, Lin SL et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005; 102: 2075\u20132080.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:25:31Z","timestamp":1648081531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,10]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12,1]]}},"alternative-id":["BF1705185"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705185","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,10]]},"assertion":[{"value":"8 June 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}